BP-897 is a drug used in scientific research which acts as a potent selective dopamine D<sub>3</sub> receptor partial agonist with an in vitro intrinsic activity of ~0.6 and ~70x greater affinity for D<sub>3</sub> over D<sub>2</sub> receptors and is suspected to have partial agonist or antagonist activity in vivo. It has mainly been used in the study of treatments for cocaine addiction. A study comparing BP-897 with the potent, antagonistic, and highly D<sub>3</sub> selective SB-277,011-A found, "SB 277011-A (1âÂÂ10 mg/kg) was able to block cue-induced reinstatement of nicotine-seeking, indicating that DRD3 selective antagonism may be an effective approach to prevent relapse for nicotine. In contrast, BP 897 did not block the cue-induced reinstatement of nicotine-seeking or nicotine-taking under the FR5 schedule."